EicOsis Human Health, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.eicosis.com
Clinical Trials
5
Active:0
Completed:3
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury
Phase 1
Recruiting
- Conditions
- Spinal Cord InjuriesNeuropathic Pain
- Interventions
- Drug: Placebo oral tabletDrug: EC5026 oral tablet
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06438471
- Locations
- 🇺🇸
AU Medical Center, Augusta, Georgia, United States
Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: EC5026 oral tabletDrug: Placebo oral tablet
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06089837
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, New Zealand
Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- Drug: EC5026 oral tabletOther: Placebo oral tablet
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04908995
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)
- Conditions
- COVID-19
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04452942
- Locations
- 🇺🇸
Stony Brook University Hospital, New York, New York, United States
Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Adults
- Interventions
- Drug: EC5026 oral capsuleOther: Placebo oral capsule
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- EicOsis Human Health Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04228302
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
News
No news found